See every side of every news story

Browser Extension

Saturday, February 22, 2025

US Edition

Subscribe Login

Volodymyr Zelenskyy

Israel-Hamas Conflict

Manchester United

onclive.com image

News from onclive.com

Topics Most Covered by onclive.com

Sources Covering Similar Topics

cancernetwork.com

targetedonc.com

cancernetwork.com

targetedonc.com

Suggest a source

Looking for a source we don't already have? Suggest one here.

News Home Page Local News Blindspot Feed International Covid-19

International North America South America Europe Asia Australia Africa

Trending Internationally Donald Trump Everton Volodymyr Zelenskyy Ukraine War Hamas

Trending in U.S.Israel-Hamas Conflict Basketball Donald Trump Elon Musk Baseball

Trending in U.K.Israel-Hamas Conflict Everton Premier League Manchester United Soccer

Trending Topics

Donald Trump Everton Volodymyr Zelenskyy Ukraine War Israel-Hamas Conflict

CompanyAbout History Mission Blog Testimonials Group Subscriptions Subscribe Gift Free Trial Careers Affiliates

HelpHelp Center FAQ Contact Us For Educators/Libraries Media Bias Ratings Ownership and Factuality Ratings Referral Code News Sources Topics

ToolsApp Browser Extension Daily Newsletter Blindspot Report Newsletter Burst Your Bubble Newsletter Timelines

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2025 Snapwise Inc

Blindspot Local

News from onclive.com

Your destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today.

We’ve aggregated 1,272 of onclive.com’s headlines and news stories over the past 3 months.

onclive.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

onclive.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Your destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today. We’ve aggregated 1,272 of onclive.com’s headlines and news stories over the past 3 months.

onclive.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about onclive.com

Where is onclive.com located?onclive.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Breaking News Topics Related to onclive.com

Israel-Hamas Conflict

Similar News Topics

Pipelinereview

targetedonc.com

Pharmacy Times

Endpoints News

ajmc.com

Top onclive.com News

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

Maryland · Maryland

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.See the Story

Dr Cortese on the Role of Venetoclax in CLL Immune Synapse Repair

Maryland · Maryland

Dr Cortese on the Role of Venetoclax in CLL Immune Synapse Repair

Matthew Cortese, MD, MPH, discusses the immunologic changes observed with venetoclax in patients with CLL.See the Story

European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC

European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC

The European Commission approved belzutifan for select VHL-associated cancers and advanced clear cell renal cell carcinoma.See the Story

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management

United States · United States

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management

D. Ross Camidge, MD, PhD, discusses ways that ALK-positive NSCLC management has changed based on 5-year follow-up data with lorlatinib in the CROWN trial.See the Story

Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer

Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer

Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.See the Story

HyperVIEW X-Ray System Receives FDA Breakthrough Device Designation for Breast Cancer Imaging

Breast Cancer · United States

HyperVIEW X-Ray System Receives FDA Breakthrough Device Designation for Breast Cancer Imaging

The HyperVIEW X-ray system has received breakthrough device designation from the FDA for contrast-enhanced imaging for diagnosis of breast cancer.See the Story

RZ-001 Earns FDA Fast Track Designation in HCC

United States · United States

RZ-001 Earns FDA Fast Track Designation in HCC

RZ-001 has received FDA fast track designation for the treatment of patients with hepatocellular carcinoma.See the Story

Dr Harrison on Investigational JAK Inhibitor–Based Combinations in Myelofibrosis

Maryland · Maryland

Dr Harrison on Investigational JAK Inhibitor–Based Combinations in Myelofibrosis

Claire Harrison, MD, FRCP, FRCPath, discusses ongoing research with first-line JAK inhibitors for patients with myelofibrosis.See the Story

Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

Panelists discuss the types of questions that real-world (RW) data can answer in comparison to with clinical trial data, and how it they can complement clinical findings in treatment decision-making.See the Story

Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies

Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies

Funda Meric-Bernstam, MD, highlights considerations with pan-tumor approvals and where testing and reporting should be improved for clarity/ease.See the Story

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

Maryland · Maryland

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.See the Story